tiprankstipranks
Advertisement
Advertisement

GB:0MH6 Stock Latest News

Ipsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis
Company AnnouncementsIpsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis
1d ago
0MH6
Ipsen’s IPN10200 Phase 3 Aesthetics Trial: What Investors Should Watch
PremiumCompany Announcements
Ipsen’s IPN10200 Phase 3 Aesthetics Trial: What Investors Should Watch
27d ago
0MH6
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
PremiumCompany Announcements
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
1M ago
0MH6
Ipsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors
PremiumCompany Announcements
Ipsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors
1M ago
0MH6
Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study
PremiumCompany Announcements
Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study
1M ago
0MH6
Ipsen’s Tazemetostat Trial in Tough Lymphoma Group Withdrawn: What Investors Should Know
PremiumCompany AnnouncementsIpsen’s Tazemetostat Trial in Tough Lymphoma Group Withdrawn: What Investors Should Know
2M ago
0MH6
Ipsen’s CaboLife Study: Real-World Cancer Data That Could Shape Cabozantinib’s Market Future
Premium
Company Announcements
Ipsen’s CaboLife Study: Real-World Cancer Data That Could Shape Cabozantinib’s Market Future
3M ago
0MH6
Ipsen’s New Study on Tazemetostat: A Potential Game-Changer for Follicular Lymphoma
Premium
Company Announcements
Ipsen’s New Study on Tazemetostat: A Potential Game-Changer for Follicular Lymphoma
4M ago
0MH6
Ipsen’s Dysport® vs. Botox®: A Completed Study on Upper Limb Spasticity
PremiumCompany Announcements
Ipsen’s Dysport® vs. Botox®: A Completed Study on Upper Limb Spasticity
4M ago
0MH6
Ipsen’s Genetic Study on PFIC: A Potential Game-Changer for Liver Disorder Diagnosis
PremiumCompany Announcements
Ipsen’s Genetic Study on PFIC: A Potential Game-Changer for Liver Disorder Diagnosis
5M ago
0MH6
Ipsen’s New Study on IPN60300: A Potential Game-Changer for Advanced Tumours
PremiumCompany Announcements
Ipsen’s New Study on IPN60300: A Potential Game-Changer for Advanced Tumours
6M ago
0MH6
Ipsen’s New Study on IPN01203: A Potential Game-Changer for Advanced Tumour Treatment
PremiumCompany Announcements
Ipsen’s New Study on IPN01203: A Potential Game-Changer for Advanced Tumour Treatment
6M ago
0MH6
Ipsen’s New Study on Odevixibat: Long-term Insights for PFIC Treatment
PremiumCompany AnnouncementsIpsen’s New Study on Odevixibat: Long-term Insights for PFIC Treatment
6M ago
0MH6
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
Premium
Company Announcements
Ipsen’s Odevixibat Study: A Potential Game-Changer for Alagille Syndrome
7M ago
0MH6
Ipsen’s Real-World Study on Cabozantinib and Nivolumab: A Potential Game-Changer for RCC Treatment
Premium
Company Announcements
Ipsen’s Real-World Study on Cabozantinib and Nivolumab: A Potential Game-Changer for RCC Treatment
7M ago
0MH6
Ipsen’s Innovative Approach to PBC: A Study on Itch and Sleep Patterns
PremiumCompany Announcements
Ipsen’s Innovative Approach to PBC: A Study on Itch and Sleep Patterns
7M ago
0MH6
Ipsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
PremiumCompany Announcements
Ipsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
7M ago
0MH6
Ipsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
PremiumCompany Announcements
Ipsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
7M ago
0MH6
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
PremiumCompany Announcements
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
7M ago
0MH6
Ipsen’s Phase II Osteosarcoma Study: A Potential Game Changer?
PremiumCompany AnnouncementsIpsen’s Phase II Osteosarcoma Study: A Potential Game Changer?
7M ago
0MH6
Ipsen’s Real-World Study on Elafibranor for PBC: A Potential Game-Changer?
Premium
Company Announcements
Ipsen’s Real-World Study on Elafibranor for PBC: A Potential Game-Changer?
7M ago
0MH6
Ipsen’s Elafibranor Study: A Potential Breakthrough for PBC Treatment
Premium
Company Announcements
Ipsen’s Elafibranor Study: A Potential Breakthrough for PBC Treatment
7M ago
0MH6

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >